Vinay Puri
Neurology with Special Qualifications in Child Neurology · Louisville, KYNPI 1275531345
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $152,691 of the $195,398 with a category attached, or 78.1%. Neurelis, Inc. accounts for 78.7% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $54,164 and has fallen 54.1% since, to $24,852 in 2025. Among neurology with special qualifications in child neurology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 306 payments — averaging $638.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurelis, Inc.$154K
- Eisai Inc.$25K
- Acadia Pharmaceuticals Inc$13K
- Zogenix Inc.$1K
- Supernus Pharmaceuticals, Inc.$444
- UCB, Inc.$351
- plus $877 from 9 others
Across 4 payments — averaging $1525.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB Biosciences Inc.$4K
- Janssen Research & Development, LLC$2K
What the payments were for
- Consulting fees$19,86810%
- Speaking & faculty fees$152,69178%
- Travel & lodging$17,1839%
- Food & beverage$5,4833%
- Education$1740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurelis, Inc. | 167 | $153,808 |
| Eisai Inc. | 30 | $25,456 |
| Acadia Pharmaceuticals Inc | 18 | $13,462 |
| Zogenix Inc. | 1 | $1,000 |
| Supernus Pharmaceuticals, Inc. | 49 | $444 |
| UCB, Inc. | 18 | $351 |
| Jazz Pharmaceuticals Inc. | 2 | $185 |
| Sunovion Pharmaceuticals Inc. | 5 | $167 |
| Travere Therapeutics, Inc. | 2 | $157 |
| Livanova USA, Inc. | 7 | $139 |
| DIXI Medical USA Corp | 1 | $103 |
| Sarepta Therapeutics, Inc. | 3 | $59 |
| Biocodex, Inc. | 1 | $26 |
| Novartis | 1 | $23 |
| PTC Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$195,398 in reported general payments places this provider in the 95th percentile of 33 neurology with special qualifications in child neurology providers in Kentucky.
See all neurology with special qualifications in child neurology providers in Kentucky →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine | 11 | $172 |
| Glycopyrrolate | 14 | $130 |
| Baclofen | 12 | $39 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Louisville
- Gregory BarnesLouisville$12K
- Darren FarberLouisville$2K
- Jaime ShoupLouisville$2K
- Christopher BartonLouisville$846
- Samir KariaLouisville$828
- Rachel EvansLouisville$554
- Elizabeth DollLouisville$375
- Emily SingerLouisville$324
- Amanda RogersLouisville$270
- Marie ClementsLouisville$216
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.